[Treatment of morning migraine. Clinical and biokinetic correlation of programmed-release dihydroergotamine]

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Drug Delivery Systems

Background:

• Migraine is a common neurological disorder often treated with dihydroergotamine.
• Existing dihydroergotamine formulations may have variable absorption and efficacy.
• Novel drug delivery systems aim to improve therapeutic outcomes and patient compliance.

Purpose of the Study:

• To evaluate the clinical efficacy and pharmacokinetic profile of a new dihydroergotamine microgranule preparation.
• To compare the programmed delivery of dihydroergotamine microgranules with a standard dihydroergotamine solution.
• To establish the correlation between plasma drug levels and therapeutic effects in migraine patients.

Main Methods:

• A comparative study involving 30 patients with morning migraine and 8 healthy subjects.
• Administration of dihydroergotamine microgranules (30 mg/24 hours) and a dihydroergotamine solution at a similar dose.
• Measurement of plasma dihydroergotamine levels in healthy subjects.
• Assessment of clinical outcomes in migraine patients.

Main Results:

• Sustained plasma levels of dihydroergotamine were observed with the microgranule preparation.
• A close correlation was found between sustained plasma levels and prolonged therapeutic effects.
• The microgranule formulation demonstrated effective programmed delivery of dihydroergotamine.
• Positive clinical results were observed in patients suffering from morning migraine.

Conclusions:

• The dihydroergotamine microgranule preparation offers a programmed delivery system for sustained drug release.
• This novel formulation shows promise for improved management of morning migraine.
• The study highlights the potential of microgranule technology in enhancing dihydroergotamine therapy.